178488

STIC-Biotech/ChemLib

From: Yaen, Christopher
Sent: Friday, February 03, 2006 9:02 AM
To: STIC-Biotech/ChemLib
Subject: 09936565

could you please run a sequence search on the followng sequence

X-Hy-Hy-X-X-Hy-X-X-X-X-Hy-Hy

wherein X = any amino acid

wherin Hy = any hydrophobic amino acid

thanks

Christopher Yaen
US Patent Office
Art Unit 1643
571-272-0838
REM 3A20
REM 3C18



****
Searcher:_____
Searcher Phone:_____
Date Searcher Picked up:_____
Date completed:_____
Searcher Prep Time:_____
Online Time:_____

****
Type of Search
NA#_____ AA#:_____
S/L:_____ Oligomer:_____
Encode/Transl:_____
Structure #:_____Text:____
Inventor:_____ Litigation:___

****
Vendors and cost where applicable
STN:_____
DIALOG:_____
QUESTEL/ORBIT:_____
LEXIS/NEXIS:_____
SEQUENCE SYSTEM:_____
WWW/Internet:_____
Other (Specify):_____


1
5
10
X-Hy-Hy-X-X-Hy-X-X-X-X-Hy-Hy


X Hy Hy X X Hy X X X X Hy Hy
M N A L Q E D T P P G P S T V F R P P T S S R P L E T P H C R E I R I G I A G I
ATGAACGCTCTCCAAGAAGATACTCCACCCGGACCATCAACGGTGTTCAGGCCACCAACAAGTTCACGGCCGTTGGAAACCCCTCACTGCAGAGAGATCCGGATTGGTATCGCTGGAATT 605
T I T L S L C G C A N A R A P T L R S A T A D N S E S T G F K N V P D L R T D Q
ACAATCACTCTATCGCTGTGTGGCTGCGCGAATGCTCGCGCTCCCACGCTAAGATCTGCAACTGCGGACAATTCAGAAAGCACTGGTTTCAAGAATGTGCCGGACTTGAGGACCGATCAA 725
P K P P S K K R S C D P S E Y R V S E L K E S L I T T T P S R P R T A K R R I R
CCCAAGCCTCCCTCGAAGAAGCGATCCTGCGACCCCTCCGAGTACAGGGTAAGCGAGCTAAAAGAAAGCTTGATTACCACTACTCCCAGCCGACCCCGAACCGCAAAAAGGCGTATAAGA 845
L *
CTGTAA 850

FIG. 3

```
=> d his nofile

     (FILE 'HOME' ENTERED AT 16:28:22 ON 09 FEB 2006)

     FILE 'LREGISTRY' ENTERED AT 16:28:31 ON 09 FEB 2006
L1           80 SEA ABB=ON  .[ILMFPWYV][ILMFPWYV]..[ILMFPWYV]....[ILMFPWYV][ILM
                FPWYV]/SQSP
L2            0 SEA ABB=ON  ^.[ILMFPWYV][ILMFPWYV]..[ILMFPWYV]....[ILMFPWYV][IL
                MFPWYV]^/SQSP

     FILE 'REGISTRY' ENTERED AT 16:29:50 ON 09 FEB 2006
L3          326 SEA ABB=ON  ^.[ILMFPWYV][ILMFPWYV]..[ILMFPWYV]....[ILMFPWYV][IL
                MFPWYV]^/SQSP
                SAVE TEMP L3 YAE565SEQ/A

     FILE 'STNGUIDE' ENTERED AT 16:30:12 ON 09 FEB 2006

     FILE 'CAPLUS' ENTERED AT 16:33:35 ON 09 FEB 2006
L4          308 SEA ABB=ON  L3
L5          164 SEA ABB=ON  L4 AND PATENT/DT
L6           47 SEA ABB=ON  L5 NOT AY>2000
L7          144 SEA ABB=ON  L4 NOT L5
L8          105 SEA ABB=ON  L7 NOT PY>2000
L9           83 SEA ABB=ON  SAUK J?/AU
L10           1 SEA ABB=ON  L4 AND L9
                D SCAN
L11         338 SEA ABB=ON  (HSP/OBI OR HEAT SHOCK PROTEIN#/OBI)(L)47/OBI OR
                HSP47/OBI
L12       73063 SEA ABB=ON  IMAGING/CW
L13      193578 SEA ABB=ON  DRUG DELIVERY SYSTEMS+OLD/CT
L14      211798 SEA ABB=ON  ANTITUMOR AGENTS+OLD/CT
L15      110519 SEA ABB=ON  CARCINOMA#/OBI
L16          14 SEA ABB=ON  (L6 OR L8) AND (L11 OR L12 OR L13 OR L14 OR L15)

     FILE 'REGISTRY' ENTERED AT 16:36:52 ON 09 FEB 2006
                D QUE L3

     FILE 'CAPLUS' ENTERED AT 16:36:52 ON 09 FEB 2006
                D QUE L16
                D IBIB ED ABS HITSEQ L16
                D IBIB ED ABS HITSEQ L16 2-14

     FILE 'HOME' ENTERED AT 16:37:31 ON 09 FEB 2006

=>
```

```
=> fil reg; d que l3; fil capl; d que l16
FILE 'REGISTRY' ENTERED AT 16:36:52 ON 09 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    7 FEB 2006  HIGHEST RN 873775-18-9
DICTIONARY FILE UPDATES:   7 FEB 2006  HIGHEST RN 873775-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L3            326 SEA FILE=REGISTRY ABB=ON  ^.[ILMFPWYV][ILMFPWYV]..[ILMFPWYV]...
                  .[ILMFPWYV][ILMFPWYV]^/SQSP
                  10        11        12

FILE 'CAPLUS' ENTERED AT 16:36:52 ON 09 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.
```

1 2 3 4 5 6 7 8 9

^ = beginning & end of seq

. = any amino acid

FILE COVERS 1907 - 9 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 8 Feb 2006 (20060208/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
L3          326 SEA FILE=REGISTRY ABB=ON  ^.[ILMFPWYV][ILMFPWYV]..[ILMFPWYV]...
                .[ILMFPWYV][ILMFPWYV]^/SQSP
L4          308 SEA FILE=CAPLUS ABB=ON  L3
L5          164 SEA FILE=CAPLUS ABB=ON  L4 AND PATENT/DT
L6           47 SEA FILE=CAPLUS ABB=ON  L5 NOT AY>2000
L7          144 SEA FILE=CAPLUS ABB=ON  L4 NOT L5
L8          105 SEA FILE=CAPLUS ABB=ON  L7 NOT PY>2000
L11         338 SEA FILE=CAPLUS ABB=ON  (HSP/OBI OR HEAT SHOCK PROTEIN#/OBI)(L)
                47/OBI OR HSP47/OBI
L12       73063 SEA FILE=CAPLUS ABB=ON  IMAGING/CW
L13      193578 SEA FILE=CAPLUS ABB=ON  DRUG DELIVERY SYSTEMS+OLD/CT
L14      211798 SEA FILE=CAPLUS ABB=ON  ANTITUMOR AGENTS+OLD/CT
L15      110519 SEA FILE=CAPLUS ABB=ON  CARCINOMA#/OBI
L16          14 SEA FILE=CAPLUS ABB=ON  (L6 OR L8) AND (L11 OR L12 OR L13 OR
                L14 OR L15)
```

=> d ibib ed abs hitseq l16

L16 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409008 CAPLUS
DOCUMENT NUMBER: 142:462265
TITLE: Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
INVENTOR(S): Noteborn, Matheus Hubertus Maria; Koch, Guus
PATENT ASSIGNEE(S): Neth.
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 454,121.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005100552	A1	20050512	US 2000-740676	20001218
NL 9002008	A	19920401	NL 1990-2008	19900912
WO 9204446	A1	19920319	WO 1991-NL165	19910911
W: AU, CA, HU, JP, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
EP 905246	A1	19990331	EP 1998-202968	19910911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5491073	A	19960213	US 1993-30335	19930308
NL 9301272	A	19950216	NL 1993-1272	19930720
WO 9503414	A2	19950202	WO 1994-NL168	19940719
WO 9503414	A3	19950302		
W: AU, CA, CN, HU, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

EP 1253201	A2	20021030	EP 2001-205103		19940719
EP 1253201	A3	20030108			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
HR 940668	B1	20001031	HR 1994-940668		19941012
US 6162461	A	20001219	US 1995-482161		19950607
PRIORITY APPLN. INFO.:			NL 1990-2008	A	19900912
			WO 1991-NL165	W	19910911
			US 1993-30335	A2	19930308
			NL 1993-1272	A	19930720
			WO 1994-NL168	W	19940719
			US 1995-482161	A1	19950607
			US 1995-454121	A2	19951130
			EP 1991-917088	A3	19910911
			YU 1991-1508	A6	19910911
			EP 1994-925638	A3	19940719

ED Entered STN: 13 May 2005

AB The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced sep. or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amts. of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clin. disease after CAV challenge. Inoculation of a mixture of lysates of cells that were sep. infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. The results indicate that expression in the same cell of at least two CAV proteins, VP1 plus VP2, is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.

IT **249727-64-8**
RL: PRP (Properties)
(unclaimed sequence; chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor)

RN 249727-64-8 CAPLUS

CN L-Leucine, L-threonyl-L-valyl-L-phenylalanyl-L-arginyl-L-prolyl-L-prolyl-L-threonyl-L-seryl-L-seryl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 TVFRPPTSSR PL ?

Absolute stereochemistry.

Fig 3 WO 9503414 A2

PAGE 1-A



PAGE 1-B



=> d ibib ed abs hitseq l16 2-14; fil hom

L16 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:282855 CAPLUS
DOCUMENT NUMBER: 140:302331
TITLE: MAGE-A3 gene-encoded HLA class II-binding tumor rejection antigen peptides for CD4+ T lymphocyte proliferation and for cancer diagnosis and therapy
INVENTOR(S): Schultz, Erwin; Chaux, Pascal; Van Snick, Jacques; Lethe, Bernard; Boon-Fallaur, Thierry; Van der Bruggan, Pierre; Stroobant, Vincent; Thielemans, Kris;

Searched by Barb O'Bryen, STIC 2-2518

Corthals, Jurgen; Heirman, Carlo
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA
SOURCE: U.S., 59 pp., Cont.-in-part of U.S. 6,291,430.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6716809	B1	20040406	US 1999-396315	19990915
US 5965535	A	19991012	US 1997-928615	19970912
US 6291430	B1	20010918	US 1998-166448	19981005
PRIORITY APPLN. INFO.:			US 1997-928615 A2	19970912
			US 1998-166448 A2	19981005

ED Entered STN: 07 Apr 2004
AB The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
IT **263328-31-0**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAGE-A3 gene-encoded HLA class II-binding tumor rejection antigen peptides for CD4+ T lymphocyte proliferation and for cancer diagnosis and therapy)
RN 263328-31-0 CAPLUS
CN L-Valine, L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-tyrosyl-L-arginyl-L-alanyl-L-arginyl-L-α-glutamyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 FLLLKYRARE PV > ← SID 4 5965535 102(e)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:142540 CAPLUS
DOCUMENT NUMBER: 136:194274
TITLE: Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators
INVENTOR(S): Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan
PATENT ASSIGNEE(S): The University of Texas System, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013850	A1	20020221	WO 2000-US22776	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000069178	A5	20020225	AU 2000-69178	20000817
PRIORITY APPLN. INFO.:			WO 2000-US22776 A	20000817

ED Entered STN: 22 Feb 2002
AB The present invention provides methods that utilize compns. containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.
IT **312593-57-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of colostrinin and constituent peptides thereof and analogs thereof as oxidative stress regulators)
RN 312593-57-0 CAPLUS
CN L-Proline, L-leucyl-L-phenylalanyl-L-phenylalanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 LFFFLPVVNV LP >

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:142539 CAPLUS

Searched by Barb O'Bryen, STIC 2-2518

DOCUMENT NUMBER: 136:194245
TITLE: Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
INVENTOR(S): Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan; Georgiades, Jerzy
PATENT ASSIGNEE(S): The University of Texas System, USA; Regen Therapeutics PLC
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013849	A1	20020221	WO 2000-US22775	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000067883	A5	20020225	AU 2000-67883	20000817
PRIORITY APPLN. INFO.:			WO 2000-US22775 A	20000817

ED Entered STN: 22 Feb 2002
AB The present invention discloses a use of colostrinin, a constituent peptide thereof, and/or an analog thereof as an immunol. regulator and as a blood cell regulator in animals including humans.
IT **312593-57-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of colostrinin and constituent peptides thereof and analogs thereof for inducing cytokines and as immunol. regulators and blood cell regulators)
RN 312593-57-0 CAPLUS
CN L-Proline, L-leucyl-L-phenylalanyl-L-phenylalanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 LFFFLPVVNV LP >

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:137234 CAPLUS
DOCUMENT NUMBER: 134:188229

Searched by Barb O'Bryen, STIC 2-2518

TITLE: Use of colostrinin, constituent peptides, and analogs as oxidative stress regulators
INVENTOR(S): Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan
PATENT ASSIGNEE(S): The University of Texas System, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001012650	A2	20010222	WO 2000-US22665		20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2000070617	A5	20010313	AU 2000-70617		20000817
PRIORITY APPLN. INFO.:			US 1999-149310P	P	19990817
			WO 2000-US22665	W	20000817

ED Entered STN: 25 Feb 2001
AB Methods are provided that use compns. containing colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, as oxidative stress regulators.
IT **312593-57-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colostrinin, peptides, and analogs as oxidative stress regulators)
RN 312593-57-0 CAPLUS
CN L-Proline, L-leucyl-L-phenylalanyl-L-phenylalanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 LFFFLPVVNV LP ?

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:136927 CAPLUS
DOCUMENT NUMBER: 134:188199
TITLE: Use of colostrinin, constituent peptides, and analogs for inducing cytokines and as blood cell regulators

Searched by Barb O'Bryen, STIC 2-2518

INVENTOR(S): Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan; Georgiades, Jerzy
PATENT ASSIGNEE(S): The University of Texas System, USA; Regen Therapeutics PLC
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001011937	A2	20010222	WO 2000-US22818	20000817
WO 2001011937	A3	20010907		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IS, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000069197	A5	20010313	AU 2000-69197	20000817
EP 1224217	A2	20020724	EP 2000-957601	20000817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-149311P P 19990817
WO 2000-US22818 W 20000817

ED Entered STN: 25 Feb 2001
AB The invention discloses a use of colostrinin, a constituent peptide thereof, and/or an analog thereof as an immunol. regulator and as a blood cell regulator in animals, including humans.
IT **312593-57-0 312593-57-0D**, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colostrinin, peptides, and analogs for inducing cytokines and as blood cell regulators)
RN 312593-57-0 CAPLUS
CN L-Proline, L-leucyl-L-phenylalanyl-L-phenylalanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 LFFFLPVVNV LP

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 312593-57-0 CAPLUS
CN L-Proline, L-leucyl-L-phenylalanyl-L-phenylalanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 LFFFLPVVNV LP

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

Searched by Barb O'Bryen, STIC 2-2518

ACCESSION NUMBER: 2000:900667 CAPLUS
DOCUMENT NUMBER: 134:51367
TITLE: MUC1 ligands for antitumor applications
INVENTOR(S): Gariepy, Jean; Yang, Shaoxian
PATENT ASSIGNEE(S): University Health Network, Can.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000077031	A2	20001221	WO 2000-CA711	20000615
WO 2000077031	A3	20010419		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-139263P P 19990615
OTHER SOURCE(S): MARPAT 134:51367
ED Entered STN: 22 Dec 2000
AB Novel ligands that bind to MUC1 are disclosed. The ligands were isolated using an improved phage display technique using MUC1 tandem repeat as a target. Uses of the ligand to detect, monitor or treat cancer as well as to prepare antibodies is also described.
IT **313228-03-4**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(MUC1 ligands for antitumor applications)
RN 313228-03-4 CAPLUS
CN L-Leucine, L-valyl-L-valyl-L-prolyl-L-valyl-L-histidyl-L-tryptophyl-L-seryl-L-arginylglycyl-L-valyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VVPVHWSRGV VL

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L16 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:881182 CAPLUS
DOCUMENT NUMBER: 134:37019
TITLE: Peptides present in Colostrinin useful in treatment of disorders of immune system and central nervous system
INVENTOR(S): Georgiades, Jerzy A.
PATENT ASSIGNEE(S): Regen Therapeutics PLC, UK
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075173	A2	20001214	WO 2000-GB2128	20000602

Searched by Barb O'Bryen, STIC 2-2518

WO 2000075173 A3 20020711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2390090	AA	20001214	CA 2000-2390090	20000602
GB 2367061	A1	20020327	GB 2001-28994	20000602
EP 1240193	A2	20020918	EP 2000-935387	20000602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003520771	T2	20030708	JP 2001-502454	20000602
CN 1544464	A	20041110	CN 2004-10028214	20000602
PRIORITY APPLN. INFO.:			GB 1999-12852 A	19990602
			WO 2000-GB2128 W	20000602

ED Entered STN: 15 Dec 2000

AB The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous system.

IT **312593-57-0P**
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(peptides present in Colostrinin useful in treatment of disorders of immune system and central nervous system)

RN 312593-57-0 CAPLUS

CN L-Proline, L-leucyl-L-phenylalanyl-L-phenylalanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 LFFFLPVVNV LP

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:666625 CAPLUS
DOCUMENT NUMBER: 133:249326
TITLE: Surface localized colligin/**hsp47** in **carcinoma** cells

Searched by Barb O'Bryen, STIC 2-2518

INVENTOR(S): Sauk, John J.
PATENT ASSIGNEE(S): University of Maryland, Baltimore, USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000054805	A1	20000921	WO 2000-US6588	20000315
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367256	AA	20000921	CA 2000-2367256	20000315
EP 1161262	A1	20011212	EP 2000-917907	20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002539175	T2	20021119	JP 2000-604877	20000315
PRIORITY APPLN. INFO.:			US 1999-124481P P	19990315
			WO 2000-US6588 W	20000315

ED Entered STN: 22 Sep 2000

AB This invention relates, e.g., to colligin/Hsp47 mols. which are expressed on the surface of carcinoma cells and to the use of such expressed mols. as targets for, e.g., therapeutic agents or imaging agents. The invention also relates to peptides which bind specifically to external domains of such surface-localized Hsp47 mols.

IT **294617-96-2**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(targeting of drugs and imaging agents to surface-localized colligin/**hsp47** in **carcinoma** cells)

RN 294617-96-2 CAPLUS
CN L-Isoleucine, L-threonyl-L-valyl-L-leucyl-L-histidyl-L-seryl-L-leucyl-L-alanyl-L-histidyl-L-glutaminyl-L-threonyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 TVLHSLAHQT FI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:718965 CAPLUS
DOCUMENT NUMBER: 131:342002
TITLE: Methods and compositions for inducing apoptosis in tumor cells

Searched by Barb O'Bryen, STIC 2-2518

INVENTOR(S): Noteborn, Matheus Hubertus Maria; Koch, Guus
PATENT ASSIGNEE(S): Leadd B.V., Neth.
SOURCE: U.S., 39 pp., Cont.-in-part of U.S. 5,491,073.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5981502	A	19991109	US 1995-485001	19950607
NL 9002008	A	19920401	NL 1990-2008	19900912
EP 905246	A1	19990331	EP 1998-202968	19910911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5491073	A	19960213	US 1993-30335	19930308
NL 9301272	A	19950216	NL 1993-1272	19930720
EP 1253201	A2	20021030	EP 2001-205103	19940719
EP 1253201	A3	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
HR 940668	B1	20001031	HR 1994-940668	19941012
US 6319693	B1	20011120	US 1995-484939	19950607

PRIORITY APPLN. INFO.:		
NL 1990-2008	A	19900912
US 1993-30335	A2	19930308
NL 1993-1272	A	19930720
EP 1991-917088	A3	19910911
WO 1991-NL165	W	19910911
YU 1991-1508	A6	19910911
US 1994-480020	A	19940607
EP 1994-925638	A3	19940719
US 1995-482161	A	19950607
US 1995-485001	A	19950607
US 1995-489666	A	19950607
US 1995-454121	A	19951130

ED Entered STN: 11 Nov 1999
AB Novel proteins of the Chicken Anemia Virus are described and compns. for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compns. containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA mols. derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which a piece of DNA is brought into a virus infectious to the host. Besides, the invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.
IT **249727-64-8**
RL: PRP (Properties)
(unclaimed sequence; methods and compns. for inducing apoptosis in tumor cells)
RN 249727-64-8 CAPLUS
CN L-Leucine, L-threonyl-L-valyl-L-phenylalanyl-L-arginyl-L-prolyl-L-prolyl-L-threonyl-L-seryl-L-seryl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 TVFRPPTSSR PL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:568940 CAPLUS
DOCUMENT NUMBER: 129:202088
TITLE: Immunological tolerance to HIV epitopes
INVENTOR(S): Scott, David; Zambidis, Elias
PATENT ASSIGNEE(S): American National Red Cross, USA
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2

Searched by Barb O'Bryen, STIC 2-2518

DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9836087	A1	19980820	WO 1998-US2766	19980213
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2279492	AA	19980820	CA 1998-2279492	19980213
EP 973933	A1	20000126	EP 1998-908538	19980213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1997-40581P P 19970213
WO 1998-US2766 W 19980213

ED Entered STN: 07 Sep 1998

AB Fusion Ig (fIg) proteins comprising one or more heterologous epitopes associated with a disease in which immune responsiveness is deleterious are useful to induce tolerance to these epitopes. HIV-1 gp120 epitopes linked in frame with an Ig heavy (H) chain are useful constructs for the induction of epitope-specific tolerance to HIV. Treatment of a subject with such a construct, or with lymphoid or hematopoietic cells expressing or secreting such fIg mols. induces specific immunol. tolerance to those epitopes. Such tolerance, by preventing production of antibodies to selected gp120 epitopes, can prevent or inhibit "bystander" apoptosis of uninfected host T cells which have bound the HIV gp120 protein to their surface CD4 mols. and are subsequently cross-linked by undesired anti-gp120 antibodies, thereby priming them for apoptosis in the presence of antigens which activate those T cells. gp120 epitopes corresponding to non-neutralizing B cell epitopes or certain T helper cell epitopes are preferred for producing the fIg mols. In addition to fIg H chains and complete Ig mols., DNA encoding such H chain and cells transformed with such DNA are provided.

IT **135540-16-8**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fusion Ig. containing T or B cell epitopes of HIV gp120 protein for inducing T cell tolerance gp120/CD4-mediated apoptosis)

RN 135540-16-8 CAPLUS

CN L-Valine, L-cysteinyl-L-valyl-L-prolyl-L-threonyl-L-asparaginyl-L-prolyl-L-valyl-L-prolyl-L-glutaminyl-L-α-glutamyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 CVPTNPVPQE VV Fig 3A WO 9836087

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:490444 CAPLUS
DOCUMENT NUMBER: 129:140670
TITLE: C-reactive protein fragment with immunomodulatory activity
INVENTOR(S): Nestor, John J., Jr.; Ho, Teresa H.; Eppstein, Deborah A.; Felgner, Philip L.; Barna, Barbara P.; Deodhar, Sharad D.
PATENT ASSIGNEE(S): Syntex (U.S.A.) Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5783179	A	19980721	US 1991-743613	19910809

PRIORITY APPLN. INFO.: US 1991-743613 19910809

ED Entered STN: 06 Aug 1998

AB Compds. having immunomodulatory activity are claimed comprising the optionally modified dodecapeptide fragment A-Ile-Tyr-Leu-Gly-Gly-Pro-Phe-Ser-Pro-Asn-Val-Leu-B (where A = acyl or H, B = OH or NR2, where each R independently is H, C1-6 alkyl, C1-6 haloalkyl, or C1-6 aralkyl) corresponding to residues 174 to 185 of C-reactive protein (CRP), pharmaceutical compns. thereof, and methods of treating cancer with the compns. Liposomal formulations containing the CRP-peptide fragment are particularly efficacious when administered in conjunction with interleukin-2.

IT **195155-73-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(C-reactive protein fragment with immunomodulatory activity)

RN 195155-73-8 CAPLUS

CN L-Leucine, L-isoleucyl-L-tyrosyl-L-leucylglycylglycyl-L-prolyl-L-phenylalanyl-L-seryl-L-prolyl-L-asparaginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 IYLGGPFSPN VL Seq ID # 1 5783179

102(e)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:341594 CAPLUS
DOCUMENT NUMBER: 129:36474
TITLE: Peptide compounds useful for modulating FGF receptor activity
INVENTOR(S): Benjamin, Howard; Chai, Ling; Findeis, Mark A.; Goodwin, William; Hundal, Arvind; Israel, David I.; Kelley, Michael; Keough, Martin P.; Lu, Kuanghui; Natoli, Farah; Peticolas, Alicia; Signer, Ethan R.; Gefter, Malcolm L.
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9821237	A2	19980522	WO 1997-US21070	19971112
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6214795	B1	20010410	US 1996-747599	19961112
CA 2270871	AA	19980522	CA 1997-2270871	19971112
AU 9853577	A1	19980603	AU 1998-53577	19971112
EP 941247	A2	19990915	EP 1997-950623	19971112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001504822	T2	20010410	JP 1998-522915	19971112
PRIORITY APPLN. INFO.:			US 1996-747599 A2	19961112
			WO 1997-US21070 W	19971112

OTHER SOURCE(S): MARPAT 129:36474
ED Entered STN: 06 Jun 1998
AB Peptide compds. are provided that bind to either of fibroblast growth factor (FGF) or a fibroblast growth factor receptor (FGFR) and, accordingly, are useful for modulating FGFR activity. Preferably, the FGFR is FGFR2-IIIC. Preferably, the FGF is basic FGF. Preferably the peptide compound comprises an amino acid sequence (Y/F)-(L/F/I)-(R/D/E/S/Y/G)-(Q/L/Y)-Y-(M/L/K/R)-(L/M/D/E/N/S)-(R/L/S/T)-(L/F/M/V). Also provided are pharmaceutical compns. comprising the peptide compds. of the invention and a pharmaceutically acceptable carrier. The invention further provides methods of modulating FGFR activity using the peptide compds. of the invention.
IT **208168-46-1 208168-46-1D**, D-amino acid-containing
208168-51-8 208168-51-8D, D-amino acid-containing
208169-36-2
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide compds. for modulating FGF receptor activity)
RN 208168-46-1 CAPLUS
CN L-Isoleucine, L-α-aspartyl-L-valyl-L-phenylalanyl-L-leucyl-L-α-aspartyl-L-methionyl-L-tyrosyl-L-glutaminyl-L-phenylalanyl-L-seryl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 DVFLDMYQFS VI

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 208168-46-1 CAPLUS
CN L-Isoleucine, L-α-aspartyl-L-valyl-L-phenylalanyl-L-leucyl-L-α-aspartyl-L-methionyl-L-tyrosyl-L-glutaminyl-L-phenylalanyl-L-seryl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 DVFLDMYQFS VI

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 208168-51-8 CAPLUS
CN L-Leucine, L-α-glutamyl-L-valyl-L-phenylalanyl-L-tyrosyl-L-arginyl-L-isoleucyl-L-tyrosyl-L-leucyl-L-seryl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 EVFYRIYLSV LL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 208168-51-8 CAPLUS
CN L-Leucine, L-α-glutamyl-L-valyl-L-phenylalanyl-L-tyrosyl-L-arginyl-L-isoleucyl-L-tyrosyl-L-leucyl-L-seryl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 EVFYRIYLSVLL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 208169-36-2 CAPLUS
CN D-Proline, D-valyl-D-leucyl-D-tryptophyl-D-asparaginyl-D-seryl-D-tyrosyl-D-isoleucyl-D-arginyl-D-leucyl-D-histidyl-D-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 VLWNSYIRLH LP

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:149186 CAPLUS
DOCUMENT NUMBER: 124:278191
TITLE: Growth inhibition by phospholipase C inhibitor peptides of colorectal **carcinoma** cells derived from familial adenomatous polyposis
AUTHOR(S): Homma, Miwako Kato; Homma, Yoshimi; Yamasaki, Moto-o; Ohmi-Imajoh, Shinobu; Yuasa, Yasuhito
CORPORATE SOURCE: Dep. Hygiene, Oncology, Tokyo Med., Dental Univ., Tokyo, 113, Japan
SOURCE: Cell Growth & Differentiation (1996), 7(3), 281-8
CODEN: CGDIE7; ISSN: 1044-9523
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 14 Mar 1996
AB The authors reported previously the enhanced phosphoinositide metabolism and constitutive activation of phosphoinositide-specific phospholipase C (PLC) in two colorectal carcinoma cell lines, KMS-4 and KMS-8, derived from familial adenomatous polyposis patients. To study the physiol. role of enhanced PLC activity in these cells, the authors analyzed the effect of PLC inhibitor (PCI) peptides on their growth and cell cycle. N-myristoylated PCI peptide, myr-PCI(Y), originally developed based on the PCI sequence of PLC-γ2, inhibited activity of purified PLC isoforms in vitro. When myr-PCI(Y) was added to KMS-4 and KMS-9 cultures, it suppressed the production of inositol trisphosphate, DNA synthesis, and cell growth, all of which were induced by serum in both KMS-4 and KMS-8 cells. The number of colonies grown in soft agar was also reduced significantly by treating KMS-8 cells with myr-PCI(Y) peptide. Flow cytometry anal. with propidium iodide labeling revealed marked decreases in the percentage of KMS-8 cells in S phase and increases in G0-G1 by the addition of myr-PCI(Y). Myr-PCI(Y) are replaced by phenylalanine and which does not inhibit phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity in vitro, did not significantly inhibit either inositol trisphosphate production or cell growth. These results indicate that the activation of PLC is essential for growth and the transformed properties of these colorectal carcinoma cells.
IT **175660-82-9 175660-83-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(growth inhibition by phospholipase C inhibitor peptides of human colorectal **carcinoma** cells derived from familial adenomatous polyposis)

RN 175660-82-9 CAPLUS

CN L-Valine, N-[1-[N-[N2-[N-[N2-[N-[N2-[N2-[N-[N-[N-(1-oxotetradecyl)glycyl]-L-leucyl]-L-tyrosyl]-L-arginyl]-L-lysyl]-L-methionyl]-L-arginyl]-L-leucyl]-L-arginyl]-L-tyrosyl]-L-prolyl]- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 GLYRKMRLRY PV

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 175660-83-0 CAPLUS
CN L-Valine, N-[1-[N-[N2-[N-[N2-[N-[N2-[N2-[N-[N-[N-(1-oxotetradecyl)glycyl]-L-leucyl]-L-phenylalanyl]-L-arginyl]-L-lysyl]-L-methionyl]-L-arginyl]-L-leucyl]-L-arginyl]-L-phenylalanyl]-L-prolyl]- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 GLFRKMRLRF PV

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A



FILE 'HOME' ENTERED AT 16:37:31 ON 09 FEB 2006

=>